scholarly article | Q13442814 |
review article | Q7318358 |
P356 | DOI | 10.1016/S0966-842X(02)02427-7 |
P698 | PubMed publication ID | 12377564 |
P2093 | author name string | Tanya Parkinson | |
P2860 | cites work | Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol | Q39473756 |
Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses | Q39907255 | ||
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. | Q43521980 | ||
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study | Q43865209 | ||
Individual acid aspartic proteinases (Saps) 1-6 of Candida albicans are not essential for invasion and colonization of the gastrointestinal tract in mice | Q43866993 | ||
Virogenomics: a novel approach to antiviral drug discovery | Q45877976 | ||
IVET and RIVET: use of gene fusions to identify bacterial virulence factors specifically induced in host tissues. | Q50118831 | ||
Computer-aided target selection-prioritizing targets for antifungal drug discovery | Q77420483 | ||
Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58 | Q22065549 | ||
Structural genomics: A pipeline for providing structures for the biologist | Q27638461 | ||
Substrate promiscuity of an aminoglycoside antibiotic resistance enzyme via target mimicry | Q27638972 | ||
Functional discovery via a compendium of expression profiles | Q27938962 | ||
Estimating the number of protein folds and families from complete genome data | Q30597194 | ||
Signature-tagged and directed mutagenesis identify PABA synthetase as essential for Aspergillus fumigatus pathogenicity | Q30897609 | ||
In vivo genetic analysis of bacterial virulence | Q33765927 | ||
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. | Q33892877 | ||
Ethical considerations in clinical pharmacogenomics research | Q33953253 | ||
Genomics-based identification of targets in pathogenic bacteria for potential therapeutic and diagnostic use. | Q34179576 | ||
Ethical and legal implications of pharmacogenomics | Q34188160 | ||
Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment | Q34188511 | ||
Antibacterial vaccine design using genomics and proteomics | Q34217850 | ||
The genomics and genetics of human infectious disease susceptibility | Q34433495 | ||
Privacy and confidentiality of genetic information: what rules for the new science? | Q34433499 | ||
Use of signature-tagged mutagenesis in pathogenesis studies | Q34521789 | ||
The pharmacogenomics of HIV therapy. | Q34574033 | ||
Comparing genomes within the species Mycobacterium tuberculosis | Q35033207 | ||
Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization | Q36558993 | ||
Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays. | Q39445682 | ||
P433 | issue | 10 Suppl | |
P921 | main subject | genomics | Q222046 |
drug discovery | Q1418791 | ||
P304 | page(s) | S22-6 | |
P577 | publication date | 2002-01-01 | |
P1433 | published in | Trends in Microbiology | Q15265732 |
P1476 | title | The impact of genomics on anti-infectives drug discovery and development | |
P478 | volume | 10 |
Q28602660 | Neglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administration |
Q33195402 | Novel therapeutic targets in Helicobacter pylori |
Q59290682 | Selection of a DNA barcode for Nectriaceae from fungal whole-genomes |
Q46023519 | The evolving role of infectomics in drug discovery. |
Q36156270 | Unraveling the secret lives of bacteria: use of in vivo expression technology and differential fluorescence induction promoter traps as tools for exploring niche-specific gene expression |
Search more.